Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln

Reuters

Nov 13

Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln

Overview

Palatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreement
Company reports fiscal Q1 net income of $4.7 mln, reversing a loss from last year
Palatin completes $18.2 mln public offering, regains NYSE American compliance

Outlook

Company plans IND submission and Phase 1 trial for PL7737 in first half of 2026
Palatin expects mid-2026 IND filing for next-gen MC4R agonists
Company received FDA Orphan Drug Designation for leptin receptor deficiency obesity

Result Drivers

BOEHRINGER INGELHEIM COLLABORATION - Revenue increase attributed to Boehringer Ingelheim collaboration, including upfront payment and milestone achievement
PUBLIC OFFERING - Successful $18.2 mln public offering strengthened balance sheet and regained NYSE American compliance

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 EPS		$4.26

Press Release: ID:nPnf1Qmja

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583560857"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583560857\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583560857?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583560857","market":"us","top_or_hot":-1,"title":"Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Palatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreement</p></li><li><p>Company reports fiscal Q1 net income of $4.7 mln, reversing a loss from last year</p></li><li><p>Palatin completes $18.2 mln public offering, regains NYSE American compliance</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans IND submission and Phase 1 trial for PL7737 in first half of 2026</p></li><li><p>Palatin expects mid-2026 IND filing for next-gen MC4R agonists</p></li><li><p>Company received FDA Orphan Drug Designation for leptin receptor deficiency obesity</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BOEHRINGER INGELHEIM COLLABORATION - Revenue increase attributed to Boehringer Ingelheim collaboration, including upfront payment and milestone achievement</p></li><li><p>PUBLIC OFFERING - Successful $18.2 mln public offering strengthened balance sheet and regained NYSE American compliance</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q1 EPS</p></td><td></td><td><p>$4.26</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nPnf1Qmja</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Palatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreement</p></li><li><p>Company reports fiscal Q1 net income of $4.7 mln, reversing a loss from last year</p></li><li><p>Palatin completes $18.2 mln public offering, regains NYSE American compliance</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans IND submission and Phase 1 trial for PL7737 in first half of 2026</p></li><li><p>Palatin expects mid-2026 IND filing for next-gen MC4R agonists</p></li><li><p>Company received FDA Orphan Drug Designation for leptin receptor deficiency obesity</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BOEHRINGER INGELHEIM COLLABORATION - Revenue increase attributed to Boehringer Ingelheim collaboration, including upfront payment and milestone achievement</p></li><li><p>PUBLIC OFFERING - Successful $18.2 mln public offering strengthened balance sheet and regained NYSE American compliance</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q1 EPS</p></td><td></td><td><p>$4.26</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nPnf1Qmja</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0HS:1","article_id":"2583560857","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583560857","pubTimestamp":1763037771,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mlnOverviewPalatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreementCompany reports fiscal Q1 net income of $4","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PTN":"Palatin Technologies Inc"},"translate_title":"Palatin第一财季收入达到880万美元，净利润470万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTN":0.9},"content_text":"Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mlnOverviewPalatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreementCompany reports fiscal Q1 net income of $4.7 mln, reversing a loss from last yearPalatin completes $18.2 mln public offering, regains NYSE American complianceOutlookCompany plans IND submission and Phase 1 trial for PL7737 in first half of 2026Palatin expects mid-2026 IND filing for next-gen MC4R agonistsCompany received FDA Orphan Drug Designation for leptin receptor deficiency obesityResult DriversBOEHRINGER INGELHEIM COLLABORATION - Revenue increase attributed to Boehringer Ingelheim collaboration, including upfront payment and milestone achievementPUBLIC OFFERING - Successful $18.2 mln public offering strengthened balance sheet and regained NYSE American complianceKey DetailsMetricBeat/MissActualConsensus EstimateQ1 EPS$4.26Press Release: ID:nPnf1QmjaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}